Home Viberzi Lawsuits

Viberzi Lawsuits

Patients who took Viberzi and suffered pancreatitis are filing lawsuits against its manufacturer, Allergan. The lawsuits claim Allergan failed to warn doctors that Viberzi increases the risk of pancreatitis in patients without gallbladders. Lawsuits also allege that there were signs of potential problems with the drug even before the FDA issued a warning in 2017.

Last Modified: May 16, 2024
Fact Checked

Editors carefully fact-check all Drugwatch.com content for accuracy and quality.

Drugwatch.com has a stringent fact-checking process. It starts with our strict sourcing guidelines.

We only gather information from credible sources. This includes peer-reviewed medical journals, reputable media outlets, government reports, court records and interviews with qualified experts.

Why Trust DrugWatch?

Drugwatch.com has been empowering patients for more than a decade

Drugwatch.com has provided reliable, trusted information about medications, medical devices and general health since 2008. We’ve also connected thousands of people injured by drugs and medical devices with top-ranked national law firms to take action against negligent corporations.

Our team includes experienced medical writers, award-winning journalists, researchers and certified medical and legal experts. Drugwatch.com is HONCode (Health On the Net Foundation) certified. This means the high-quality information we provide comes from credible sources, such as peer-reviewed medical journals and expert interviews.

The information on Drugwatch.com has been medically and legally reviewed by more than 30 expert contributors, including doctors, pharmacists, lawyers, patient advocates and other health care professionals. Our writers are members of professional associations, including American Medical Writers Association, American Bar Association, The Alliance of Professional Health Advocates and International Society for Medical Publication Professionals.

About Drugwatch.com

  • Assisting patients and their families since 2008.
  • Helped more than 12,000 people find legal help.
  • A+ rating from the Better Business Bureau.
  • 5-star reviewed medical and legal information site.
Learn More About Us


"Drugwatch opened my eyes to the realities of big pharmacy. Having a family member with major depression and anxiety, I was looking for information on her medications. I found information that was very helpful, that her psychiatrist never told her."
Marianne Zahren Patient’s Family Member
  • Google Business Rating
  • BBB A+ Rating Logo

Latest Status of Viberzi Lawsuits

There have been no major settlements or verdicts in Viberzi lawsuits. As of June 2024, all cases have been filed as individual lawsuits and have not been consolidated into a multidistrict litigation. Drugwatch’s partners are not currently accepting Viberzi lawsuits.

Viberzi lawsuits allege that Allergan failed to warn about the increased risk of potentially fatal pancreatitis in patients without a gallbladder who were prescribed Viberzi. 

Symptoms of pancreatitis include abdominal pain, inflammation, pancreas damage, and complications affecting vital organs. Severe pancreatitis can be life-threatening, with instances culminating in fatalities.

Viberzi Patient Experience

When Erin Duncan was prescribed Viberzi in 2016, she hoped the medication would relieve her symptoms of irritable bowel syndrome. But after taking just one dose of the drug, the 46-year-old California woman landed in the hospital.

Lab tests and imaging showed that Duncan was suffering from acute pancreatitis, an inflammation of the pancreas. The condition is serious and sometimes deadly. It can lead to complications such as kidney failure, respiratory failure, diabetes and pancreatic cancer — and Duncan says Viberzi maker Allergan is entirely to blame.

In September 2018, Duncan filed an eight-count lawsuit against Allergan in U.S. District Court for the Central District of California.

In her suit, she alleges the drugmaker failed to “adequately test for and warn” that Viberzi created an increased risk of pancreatitis in patients like herself who don’t have gallbladders.

Though Duncan was discharged from the hospital after four days, she says she “remains at an increased risk” for recurrent attacks of pancreatitis and lives in fear she may one day develop pancreatic cancer because of the inflammation.

As of early October 2018, Allergan had not yet responded to the initial complaint filed by Duncan, which is among the first Viberzi suits filed over the drug’s side effects.

The company had 21 days to respond to the allegations, according to court filings.

Similar lawsuits could follow. According to the FDA, outpatient retail pharmacies in the U.S. dispensed about 64,000 Viberzi prescriptions from May 2015 through July 2016, though it’s unclear how many people developed pancreatitis while taking the drug.

Gallbladder Problems Spark FDA Warning

When the FDA approved Viberzi in 2015, the drug was hailed by its manufacturers as a “first step to providing physicians with a new, evidence-based, treatment option” for adults with irritable bowel syndrome with diarrhea (IBS-D).

But nearly two years later, in March 2017, the FDA issued a warning that the drug should not be used in patients who’ve had their gallbladders removed.

Did You Know?
In April 2017, Allergan changed Viberzi’s prescribing label to warn that the drug should not be used in patients without a gallbladder.

The regulatory agency said it had received 120 reports between May 2015 and February 2017 of patients who’d developed serious cases of pancreatitis while taking Viberzi. Seventy-six of those patients ended up in the hospital and two died. At least 56 of the ill patients — including the two who died — did not have their gallbladders.

The European Medicines Agency, the European Union’s equivalent to the FDA, issued similar warnings about the drug even earlier, in July 2016.

Reports to FDA Between May 2015 & February 2017

FDA reports graph

Suit Says Clinical Trials Raised Red Flags

Litigants, such as Duncan, allege that there were signs of potential problems with the drug even before the FDA warning — and contend that the drugmaker did not properly investigate them.

Duncan’s complaint notes that at least 40 patients participating in Vibrezi clinical trials stopped taking the drug because of abdominal pain. According to the lawsuit, half of those events occurred during the first 24 hours of therapy, but the “vast majority” of those patients were not tested to see if they were suffering from pancreatitis.

“Properly designed and executed clinical trials would have led the original May 2015 label to contraindicate use in patients without gallbladders, Because the FDA did not have the benefit of data from adequately designed and executed clinical trials, it did not require contraindication in patients without a gallbladder.”

Please seek the advice of a medical professional before making health care decisions.